Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.65 |
| ▸ | PTGES | O14684 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15422948 | 0.92 | HDAC3 (0.71) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL5069836 | 0.91 | PTGS2 (0.64) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL5920852 | 0.91 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL5920875 | 0.89 | PTGS2 (0.71) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL27616962 | 0.89 | PTGS2 (0.61) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15423097 | 0.89 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15408158 | 0.89 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL5073564 | 0.89 | PTGS2 (0.70) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15423145 | 0.88 | PTGS1 (0.70) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15408562 | 0.88 | HDAC3 (0.63) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562910-A1 | CELECOXIB PRODRUG | Pharmacia Corporation (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004043934-A1 | CELECOXIB PRODRUG | PHARMACIA CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| US-20040092566-A1 | Celecoxib prodrug | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | claimed |
| US-8859781-B2 | No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents | Euclises Pharmaceuticals, Inc. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. | 2014-01-16 | — | — | US | disclosed |
| CN-1711247-A | Celecoxib prodrug | PHARMACIA CORP (US) | 2005-12-21 | — | — | CN | disclosed |
| EP-1562910-A1 | CELECOXIB PRODRUG | Pharmacia Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562910-A1 | CELECOXIB PRODRUG | Pharmacia Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1446118-A1 | ORAL DOSAGE FORM OF A SULFONAMIDE PRODRUG SUCH AS PARECOXIB | Pharmacia Corporation (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004043934-A1 | CELECOXIB PRODRUG | PHARMACIA CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043934-A1 | CELECOXIB PRODRUG | PHARMACIA CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040092566-A1 | Celecoxib prodrug | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040092566-A1 | Celecoxib prodrug | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PHARMACIA CORPORATION | 2003-05-29 | — | — | US | disclosed |
| WO-2003041705-A1 | ORAL DOSAGE FORM OF A SULFONAMIDE PRODRUG SUCH AS PARECOXIB | PHARMACIA CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | NOS1, NOS2, PTGS1 | HDAC3 1649/4885HDAC1 1800/4885HDAC2 3270/4885 |
| US-20040092566-A1 | Celecoxib prodrug | PTGES2, PTGS2, PTGS1 | HDAC3 85/4885HDAC1 191/4885HDAC2 107/4885 |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PTGS2, PTGES2, SI | HDAC3 1011/4885HDAC1 1197/4885HDAC2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.